Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$0.97
-5.1%
$1.28
$0.95
$5.62
$90.03M2.341.59 million shs595,454 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.57
-2.2%
$26.15
$24.48
$31.54
$145.10B0.6136.65 million shs29.91 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-1.92%0.00%-22.14%-39.64%-80.50%
Pfizer Inc. stock logo
PFE
Pfizer
-0.27%+0.26%-0.70%-2.27%-4.48%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
2.7513 of 5 stars
3.51.00.00.03.23.30.6
Pfizer Inc. stock logo
PFE
Pfizer
4.919 of 5 stars
2.33.04.24.22.83.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
3.00
Buy$10.33967.49% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.63
Moderate Buy$31.9224.87% Upside

Current Analyst Ratings Breakdown

Latest CRBU and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/19/2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
2/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
1/28/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$30.00 ➝ $29.00
1/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$31.00 ➝ $29.00
1/7/2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $11.00
(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$9.99M9.01N/AN/A$4.17 per share0.23
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.28$4.01 per share6.38$15.81 per share1.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$102.07M-$1.65N/AN/AN/A-1,290.81%-45.46%-38.07%5/6/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4118.158.440.6412.62%19.47%8.09%4/29/2025 (Estimated)

Latest CRBU and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/10/2025Q4 2024
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.40-$0.39+$0.01-$0.39$2.11 million$2.08 million
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.73%+2.50%121.99%16 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/A
7.38
7.38
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73

Institutional Ownership

CompanyInstitutional Ownership
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
77.51%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
9.50%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
10093.01 million81.95 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable

Recent News About These Companies

5 Large Drug Stocks to Watch as Industry Recovers
Analysts Issue Forecasts for Pfizer's Q2 Earnings (NYSE:PFE)
Pfizer Inc. stock logo
Pfizer (NYSE:PFE) Shares Down 0.7% - Here's What Happened
Pfizer Inc. stock logo
Dividend Stocks To Consider - March 23rd

New MarketBeat Followers Over Time

Media Sentiment Over Time

Caribou Biosciences stock logo

Caribou Biosciences NASDAQ:CRBU

$0.97 -0.05 (-5.10%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Pfizer stock logo

Pfizer NYSE:PFE

$25.56 -0.58 (-2.20%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.